Predictive Factors for Biochemical Recurrence in Radical Prostatectomy Patients

Overview

Journal Cent European J Urol

Specialty Urology

Date 2016 Feb 9

PMID 26855791

Citations 3

Authors

Hakan Turk

Orcun Celik

Sitki Un

Mehmet Yoldas

Cemal Selcuk Isoglu

Mustafa Karabicak

Batuhan Ergani

Gokhan Koc

Ferruh Zorlu

Yusuf Ozlem Ilbey

Affiliations

Soon will be listed here.

Abstract

Introduction: Radical prostatectomy (RP) is considered the best treatment for the management of localized prostate cancer in patients with life expectancy over 10 years. However, a complete recovery is not guaranteed for all patients who received/underwent RP treatment. Biochemical recurrence is frequently observed during the post-operative follow-up period. The main objective in this study is to evaluate the predictive factors of biochemical recurrence in localized prostate cancer patients who underwent RP surgery.

Material And Methods: The study included 352 patients with prostate cancer treated by RP at a single institution between February 2004 and June 2014. Detailed pathological and follow-up data of all patients were obtained and analyzed to determine the results.

Results: Mean follow-up duration was 39.7 months. 83 patients (23%) experienced biochemical recurrence (BCR) during the follow-up period. Mean BCR duration range was 6.56 (1-41) months. In multivariate logistic regression analysis, Gleason score (GS), PSA and extra-capsular tumour spread (ECS) variables were found to be statistically significant as BCR predictive factors.

Conclusions: According to our study results, it is thought that PSA, GS and ECS can all be used for guidance in choosing a treatment modality for post-RP biochemical recurrence and metastatic disease as predictive factors. However, there is no consensus in this matter and it is still debated.

Citing Articles

Prognostic significance of a novel indicator (PSA/PSA) for PSA recurrence in patients after radical prostatectomy.

Zhou Z, Xu Y, Li Q, Yan W, Zhou Y, Zheng Z Cancer Manag Res. 2019; 11:5777-5783.

PMID: 31417316 PMC: 6601339. DOI: 10.2147/CMAR.S197521.

Analysis of Circulating Tumor Cells in Patients with Non-Metastatic High-Risk Prostate Cancer before and after Radiotherapy Using Three Different Enumeration Assays.

Budna-Tukan J, Swierczewska M, Mazel M, Cieslikowski W, Ida A, Jankowiak A Cancers (Basel). 2019; 11(6).

PMID: 31185699 PMC: 6627099. DOI: 10.3390/cancers11060802.

Letter to the Editor.

Sertkaya Z Cent European J Urol. 2016; 69(1):122.

PMID: 27123340 PMC: 4846736. DOI: 10.5176/ceju.2016.l1.

References

Lee J, Lee S, Yun C, Jeon B, Kim J, Ha H . Prediction of perineural invasion and its prognostic value in patients with prostate cancer. Korean J Urol. 2010; 51(11):745-51. PMC: 2991570. DOI: 10.4111/kju.2010.51.11.745. View

Kupelian P, Katcher J, Levin H, Zippe C, Klein E . Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology. 1996; 48(2):249-60. DOI: 10.1016/S0090-4295(96)00167-7. View

Lowe B, Lieberman S . Disease recurrence and progression in untreated pathologic stage T3 prostate cancer: selecting the patient for adjuvant therapy. J Urol. 1997; 158(4):1452-6. View

Bostwick D, Grignon D, Hammond M, Amin M, Cohen M, Crawford D . Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000; 124(7):995-1000. DOI: 10.5858/2000-124-0995-PFIPC. View

Partin A, Piantadosi S, Sanda M, Epstein J, Marshall F, Mohler J . Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology. 1995; 45(5):831-8. DOI: 10.1016/S0090-4295(99)80091-0. View

Budaus L, Isbarn H, Eichelberg C, Lughezzani G, Sun M, Perrotte P . Biochemical recurrence after radical prostatectomy: multiplicative interaction between surgical margin status and pathological stage. J Urol. 2010; 184(4):1341-6. DOI: 10.1016/j.juro.2010.06.018. View

Salomon L, Anastasiadis A, Johnson C, McKiernan J, Goluboff E, Abbou C . Seminal vesicle involvement after radical prostatectomy: predicting risk factors for progression. Urology. 2003; 62(2):304-9. DOI: 10.1016/s0090-4295(03)00373-x. View

Partin A, Pearson J, Landis P, Carter H, Pound C, Clemens J . Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology. 1994; 43(5):649-59. DOI: 10.1016/0090-4295(94)90180-5. View

Kunz I, Musch M, Roggenbuck U, Klevecka V, Kroepfl D . Tumour characteristics, oncological and functional outcomes in patients aged ≥ 70 years undergoing radical prostatectomy. BJU Int. 2012; 111(3 Pt B):E24-9. DOI: 10.1111/j.1464-410X.2012.11368.x. View

10.

Freedland S, Aronson W, Presti Jr J, Amling C, Terris M, Trock B . Predictors of prostate-specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy. Cancer. 2004; 100(8):1633-8. DOI: 10.1002/cncr.20122. View

11.

Lerner S, Blute M, Zincke H . Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity. J Urol. 1995; 154(4):1447-52. View

12.

Swindle P, Eastham J, Ohori M, Kattan M, Wheeler T, Maru N . Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol. 2008; 179(5 Suppl):S47-51. DOI: 10.1016/j.juro.2008.03.137. View

13.

Epstein J, Carmichael M, Walsh P . Adenocarcinoma of the prostate invading the seminal vesicle: definition and relation of tumor volume, grade and margins of resection to prognosis. J Urol. 1993; 149(5):1040-5. DOI: 10.1016/s0022-5347(17)36291-2. View

14.

van den Bergh R, van Vugt H, Korfage I, Steyerberg E, Roobol M, Schroder F . Disease insight and treatment perception of men on active surveillance for early prostate cancer. BJU Int. 2009; 105(3):322-8. DOI: 10.1111/j.1464-410X.2009.08764.x. View

15.

Fowler Jr F, Barry M, Lu-Yao G, Roman A, Wasson J, WENNBERG J . Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988-1990 (updated June 1993). Urology. 1993; 42(6):622-9. DOI: 10.1016/0090-4295(93)90524-e. View

16.

Han M, Partin A, Pound C, Epstein J, Walsh P . Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001; 28(3):555-65. DOI: 10.1016/s0094-0143(05)70163-4. View

17.

van den Bergh R, Essink-Bot M, Roobol M, Schroder F, Bangma C, Steyerberg E . Do anxiety and distress increase during active surveillance for low risk prostate cancer?. J Urol. 2010; 183(5):1786-91. DOI: 10.1016/j.juro.2009.12.099. View

18.

Lu-Yao G, Potosky A, Albertsen P, Wasson J, Barry M, WENNBERG J . Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. J Natl Cancer Inst. 1996; 88(3-4):166-73. DOI: 10.1093/jnci/88.3-4.166. View

19.

Simon M, Kim S, Soloway M . Prostate specific antigen recurrence rates are low after radical retropubic prostatectomy and positive margins. J Urol. 2006; 175(1):140-4. DOI: 10.1016/S0022-5347(05)00050-9. View

20.

Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C . Cancer statistics, 2006. CA Cancer J Clin. 2006; 56(2):106-30. DOI: 10.3322/canjclin.56.2.106. View